Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up
Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Nephrology
2020-09-01
|
Series: | Kidney Research and Clinical Practice |
Subjects: | |
Online Access: | https://doi.org/10.23876/j.krcp.20.015 |
id |
doaj-2cbb7214c6974dfb9a11dcf37d1dabfa |
---|---|
record_format |
Article |
spelling |
doaj-2cbb7214c6974dfb9a11dcf37d1dabfa2020-11-25T03:06:50ZengThe Korean Society of NephrologyKidney Research and Clinical Practice2211-91322020-09-0139333434310.23876/j.krcp.20.015j.krcp.20.015Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-upAntonio Lacquaniti0Patrizio Pasqualetti1Teresa Casuscelli di Tocco2Susanna Campo3Stefania Rovito4Maurizio Bucca5Antonino Ragusa6Paolo Monardo7Nephrology and Dialysis Unit, Papardo Hospital, Messina, ItalyService of Medical Statistics & IT (SeSMIT), Fatebenefratelli Foundation for Health Research and Education, Rome, ItalyNephrology and Dialysis Unit, Papardo Hospital, Messina, ItalyNephrology and Dialysis Unit, Papardo Hospital, Messina, ItalyNephrology and Dialysis Unit, Papardo Hospital, Messina, ItalyNephrology and Dialysis Unit, Papardo Hospital, Messina, ItalyNephrology and Dialysis Unit, Papardo Hospital, Messina, ItalyNephrology and Dialysis Unit, Papardo Hospital, Messina, ItalyBackground : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have been previously treated with ferric gluconate (FX). Markers of iron metabolism, erythropoietin (EPO) doses, and effects on anemic status have been analysed. Methods : : The study was performed with a follow up period of 4 years, when patients were treated before with FX and then switched to FCM. A total of 25 patients were included in the study. Results : : FCM increased transferrin saturation (TSAT) levels by 11.9% (P < 0.001) with respect to FX. Events of TSAT less than 20% were reduced during FCM. The monthly dose of EPO was reduced in the FCM period (-6,404.1 international unit [IU]; 95% confidence interval, -10,643.5 IU; -2,164.6 IU; P = 0.003), as well as the erythropoietin resistance index (P = 0.004). During the period with FCM, ferritin levels were higher than during FX (P < 0.001), while transferrin was reduced (P = 0.001). Conclusion : : During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. Stable and on target levels of hemoglobin were maintained with better control of anemia through high levels of ferritin and TSAT.https://doi.org/10.23876/j.krcp.20.015anemiaerythropoietin resistance indexferric carboxymaltosehemodialysis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Antonio Lacquaniti Patrizio Pasqualetti Teresa Casuscelli di Tocco Susanna Campo Stefania Rovito Maurizio Bucca Antonino Ragusa Paolo Monardo |
spellingShingle |
Antonio Lacquaniti Patrizio Pasqualetti Teresa Casuscelli di Tocco Susanna Campo Stefania Rovito Maurizio Bucca Antonino Ragusa Paolo Monardo Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up Kidney Research and Clinical Practice anemia erythropoietin resistance index ferric carboxymaltose hemodialysis |
author_facet |
Antonio Lacquaniti Patrizio Pasqualetti Teresa Casuscelli di Tocco Susanna Campo Stefania Rovito Maurizio Bucca Antonino Ragusa Paolo Monardo |
author_sort |
Antonio Lacquaniti |
title |
Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up |
title_short |
Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up |
title_full |
Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up |
title_fullStr |
Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up |
title_full_unstemmed |
Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up |
title_sort |
ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up |
publisher |
The Korean Society of Nephrology |
series |
Kidney Research and Clinical Practice |
issn |
2211-9132 |
publishDate |
2020-09-01 |
description |
Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have been previously treated with ferric gluconate (FX). Markers of iron metabolism, erythropoietin (EPO) doses, and effects on anemic status have been analysed. Methods : : The study was performed with a follow up period of 4 years, when patients were treated before with FX and then switched to FCM. A total of 25 patients were included in the study. Results : : FCM increased transferrin saturation (TSAT) levels by 11.9% (P < 0.001) with respect to FX. Events of TSAT less than 20% were reduced during FCM. The monthly dose of EPO was reduced in the FCM period (-6,404.1 international unit [IU]; 95% confidence interval, -10,643.5 IU; -2,164.6 IU; P = 0.003), as well as the erythropoietin resistance index (P = 0.004). During the period with FCM, ferritin levels were higher than during FX (P < 0.001), while transferrin was reduced (P = 0.001). Conclusion : : During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. Stable and on target levels of hemoglobin were maintained with better control of anemia through high levels of ferritin and TSAT. |
topic |
anemia erythropoietin resistance index ferric carboxymaltose hemodialysis |
url |
https://doi.org/10.23876/j.krcp.20.015 |
work_keys_str_mv |
AT antoniolacquaniti ferriccarboxymaltoseversusferricgluconateinhemodialysispatientsreductionoferythropoietindosein4yearsoffollowup AT patriziopasqualetti ferriccarboxymaltoseversusferricgluconateinhemodialysispatientsreductionoferythropoietindosein4yearsoffollowup AT teresacasuscelliditocco ferriccarboxymaltoseversusferricgluconateinhemodialysispatientsreductionoferythropoietindosein4yearsoffollowup AT susannacampo ferriccarboxymaltoseversusferricgluconateinhemodialysispatientsreductionoferythropoietindosein4yearsoffollowup AT stefaniarovito ferriccarboxymaltoseversusferricgluconateinhemodialysispatientsreductionoferythropoietindosein4yearsoffollowup AT mauriziobucca ferriccarboxymaltoseversusferricgluconateinhemodialysispatientsreductionoferythropoietindosein4yearsoffollowup AT antoninoragusa ferriccarboxymaltoseversusferricgluconateinhemodialysispatientsreductionoferythropoietindosein4yearsoffollowup AT paolomonardo ferriccarboxymaltoseversusferricgluconateinhemodialysispatientsreductionoferythropoietindosein4yearsoffollowup |
_version_ |
1724672066995617792 |